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Introduction
Despite the significant improvements in the field of allogeneic hematopoietic cell transplantation (allo-HCT), graft-versus-host disease (GVHD) remains the major cause of transplant related morbidity and mortality.
1 Multiple cell types, cytokines, chemokines, and signaling pathways involved in the innate and adaptive immune response are implicated in the development of GVHD. 2 Further understanding of the molecular mechanisms that regulate the pathophysiology of GVHD is highly desirable.
MicroRNAs (miRs) are endogenous single-stranded and non-coding RNAs of 19-22 nucleotides.
3,4
The seed sequence in miRs can bind to the partially complimentary sequence in their target mRNAs, resulting in degradation of these target mRNAs and translational repression. 3, 4 The miRs regulate almost every known cellular process and play crucial roles in numerous biological and pathological responses. Pertaining to miRs relation to GVHD, an elegant pre-clinical study demonstrated that a specific miR-mRNA network regulates allogeneic T-cell responses. 5 A recent clinical study illustrated miR-423, miR-199a-3p, miR-93, and miR-377 were up-regulated in the plasma of patients with acute GVHD, which were then validated as biomarkers to predict GVHD occurrence. 6 Other studies have indicated that miR-100, 7 miR-34a, 8 and miR-155 9 play a potentially significant role in GVHD. Specific targeting of miR-155 using locked nucleic acid (LNA)-modified oligonucleotides (also known as antagomirs) effectively mitigates GVHD, 9 leading to a current clinical trial to further establish the significance of miR-155 in GVHD (ClinicalTrials.gov identifier: NCT01521039). Evidently, miRs not only regulate the development of GVHD, but may also potentially be used as biomarkers and therapeutic targets.
10
The miR-17-92 cluster, one of the best characterized miRs, encodes 6 miRs including miR-17, 18a, 19a, 20a, 19b-1, and 92-1 (Fig. S1 ). Originally, this miR cluster was found to be involved in
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11 However, recent research has uncovered unexpected roles of its members in a wide variety of settings including normal development, cardiovascular disease, and aging. 12, 13 Furthermore, the miR-17-92 cluster plays critical roles in early B-cell development, homeostasis, and T-cell differentiation, survival, and function [14] [15] [16] and its regulatory functions have been explored in antiinfection, anti-tumor, and autoimmune responses. [13] [14] [15] 17 However, the role this cluster plays in modulating T-cell alloresponses in GVHD and graft-versus-leukemia (GVL) activity has not been elucidated. In the current study, we have investigated how the miR-17-92 cluster regulates T cell response to alloantigens in murine models of allogeneic bone marrow transplantation (allo-BMT), and revealed that absence or blockade of miR-17-92 significantly reduces GVHD while preserving the GVL effect.
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From BMT models. T-cell purification from spleen and lymph nodes was done by negative depletion using magnetic beads as previously described. 18 Major histocompatibility complex (MHC)-mismatched (B6→BALB/c), MHC-matched but minor histocompatibility antigen (MiHA)-mismatched (B6→BALB.B), and haploidentical (B6→BDF1) BMT models were used as previously established.
Material and Methods

Mice
19
Recipients were monitored for survival and body weight loss twice/week. The GVL models with A20 B-cell lymphoma or p815 mastocytoma were established as previously described. 20 Representative samples of GVHD target organs were excised from recipients 14 days post-BMT and subjected to pathology scoring as previously described.
18,20
Treatment with LNA antagomirs. The anti-miR-17 and anti-miR-19 antagomirs are 10-mer seedtargeting LNA oligonucleotides, which were designed as shown in supplemental figure 1 and synthesized in Exiqon (Woburn, MA). Recipient mice were treated with anti-miR-17, anti-miR-19, or
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Flow cytometry and serum cytokine detection. Mononuclear cells were isolated from recipient spleen, liver, gut, and lung as previously described 18, 20, 21 and stained for surface molecules and intracellular cytokines using standard flow cytometry protocols. Stained cells were analyzed using Diva software, LSR II (BD Biosciences, San Jose, CA), and FlowJo (TreeStar, Ashland, OR). Cytokine levels in recipient serum were quantified using a cytometric bead assay according to the manufacturer's instructions (BD Biosciences, San Jose, CA).
22
Statistics. For comparison of recipient survival among groups in GVHD experiments, the log-rank test was used to determine statistical significance. To compare body weight changes, pathology scores, cytokine levels, and receptor levels, a Student t test was performed.
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Results
miR-17-92 promotes allogeneic T-cell responses in vivo
The miR-17-92 cluster promotes T-cell proliferation, enhances Th1 differentiation, protects T cells from activation-induced cell death (AICD), and suppresses the generation of induced regulatory T cells (iTregs) under polyclonal stimulation in vitro.
14 Therefore, we hypothesized that this miR cluster plays an essential role in T-cell alloresponses. To test this, we utilized B6 mice with miR-17-92 conditional KO on the T cell lineage (miR-17-92 fl/fl CD4-Cre + ). The T cell subsets including CD4, CD8, Tregs, naïve, and memory T cells were comparable between WT and KO mice (data not shown). We then compared the responses of WT and KO T cells after adoptively transferring them into lethally irradiated allogeneic recipients. We observed that the KO T cells had a substantially reduced ability to proliferate and produce IFNγ as compared to WT counterparts, reflected by percentage and number of donor T cells (Fig. 1A-B) , CFSE dilution (Fig. 1C-D) , and percentage and number of IFNγ + cells in donor T cells (Fig. 1E-F) . Interestingly, the KO CD4 T cells had an increased rate of cell death among fast-dividing cells (CFSE low ) but a decreased rate of cell death among slow-dividing cells (CFSE   high   ) compared to their WT counterparts (Fig. 1G-H) . Decreased rate of cell death in KO CD4 T cells was also observed after being transferred into syngeneic recipients where T cells were undergoing homeostatic proliferation (data not shown). On the other hand, miR-17-92 had no effect on cell death of CD8 T cells, regardless of cell division (Fig. 1G-H) . These results suggest that miR-17-92 enhances T-cell proliferation and activation in response to alloantigens. Furthermore, miR-17-92 differentially regulates CD4 vs. CD8 T cells and homeostatic vs. antigen-driven responses, which mainly protects antigen-driven CD4 T cells from undergoing cell death.
miR-17-92 is essential for T cells to induce GVHD
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From Because miR-17-92 is critical for T-cell proliferation, IFNγ production, and survival in response to alloantigens (Fig. 1) , we further hypothesized that KO T cells would fail to induce GVHD. Using a MHC-mismatched B6→BALB/c model and titrating the dose of donor T cells, we found that recipients of WT T cells developed severe and lethal GVHD in a dose-dependent manner, while recipients of KO T cells all survived long-term (Fig. 2A, p < .001 ) with significantly less weight loss (Fig. 2B ) and milder pathological injuries in the liver and gut (Fig. 2C-D) . Thirty days after BMT, recipients of KO T cells had significantly improved donor-derived B-cell reconstitution in the peripheral blood as compared with recipients of WT T cells (Fig. S2A) . While the majority of donor-derived T cells originated from mature T cells (H2K b+ Ly5.1 -) in the recipients with WT T cells, the majority of donor T cells were BM-derived T cells (H2K b+ Ly5.1 + ) in the recipients with KO T cells (Fig. S2B) .
Consistently, 80 days post-BMT, the recipients of KO T cells had significantly more donor BMderived T and B cells but much fewer transferred T cells in their spleens than those of survived WT T cell recipients (Fig. S3) , indicating that recipients of KO T cells survived long-term without severe GVHD.
In clinical HCT, most patients receive grafts from MHC-matched but MiHA-mismatched donors. In an effort to extend our studies to better mimic a clinical scenario, we used the B6→BALB.b (both H2 b ) model with at least 29 different MiHA loci. 23 While the recipients of WT T cells suffered modest GVHD with less than 60% survival and severe weight loss, the recipients of KO T cells had mild GVHD with 100% long-term survival (p < .05) and minimal weight loss (Fig. 2E-F) . In parallel, the reconstitution of donor BM-derived T and B cells in spleen was significantly better in the recipients of KO T cells as compared to those of WT T cells (Fig. S4A-B) . In addition, a significantly improved thymus cellularity and function, reflected by the number of total and CD4 + CD8 + thymocytes, were found in recipients of KO T cells. Given the thymus is a sensitive GVHD target organ, which is
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miR-17-92 regulates T-cell expansion and migration
Development of GVHD requires donor T-cell expansion in lymphoid organs and migration into target organs through up-regulating chemokine receptors and integrins. 24 We examined the presence of donor T cells in recipient spleens (secondary lymphoid organ) and livers (GVHD target organ) 14 days following allo-BMT. We found that KO CD4 T cells were fewer than WT CD4 T cells in the recipient spleen (Fig. 3A) , and the difference was much more dramatic in the liver (Fig. 3B) . While WT and KO CD8 T cells were comparable in the spleen, KO cells were significantly fewer than WT cells in the liver (Fig. 3A-B) . We observed that both CD4 and CD8 KO T cells had significantly reduced expression of CXCR3 and α 4β7 as compared to WT counterparts (Fig. 3C-F) . In addition, KO T cells expressed significantly lower levels of CXCR3 in the liver (data not shown) and of α 4β7 in the gut and mesenteric lymph node (MLN) (Fig. S5A ). These data suggest that miR-17-92 is required for CD4, but not CD8, T-cell expansion after allo-BMT. In addition, miR-17-92 may promote T-cell migration to GVHD target organs.
miR-17-92 controls T-cell differentiation
Naïve CD4 T cells can differentiate into various T cell subsets including Th1, Th2, Th17, and Treg cells. With regards to GVHD, Th1 and Th17 cells are considered to be pathogenic, whereas Tregs are suppressive. 25 We therefore evaluated how miR-17-92 affects T-cell differentiation after allo-BMT.
We found that WT T cells differentiated predominately into IFNγ-producing Th1 cells, with quite few IL-4/5-producing Th2 or Foxp3 + iTregs presented in recipient spleens (Fig. 4A-B) . On the contrary, 1 0 KO T cells differentiated into significantly less Th1 cells and toward Th2 and iTregs cells. The effect of miR-17-92 on T-cell differentiation was also evident in GVHD target organs such as the liver (Fig.   S6 ). In the absence of miR-17-92, KO CD4 T cells also produced significantly lower levels of IFNγ and IL-17 in recipient gut and MLN, which is consistent with the alleviated gut damage in the recipients of KO T cells (Fig. S5B-C) . The intracellular cytokine expression was further supported by a similar cytokine production pattern in the serum. The levels of IFNγ were significantly reduced while the levels of IL-10 were significantly increased in recipients transferred with miR-17-92 KO T cells, compared to those with WT T cells (Fig. 4C) S7) . Thus, we conclude that iTregs generated from KO T cells likely contributed to the reduction of GVHD.
miR-17-92 regulates T-cell response intrinsically
Our data indicates that deficiency of miR-17-92 in T cells strongly inhibits CD4 T-cell expansion, Th1 differentiation, and T-cell migration to target organs. In order to test the endogenous defects of these KO T cells, we utilized a competitive assay to directly compare the responses of WT vs. KO T cells in the same recipient after allo-BMT. While WT and KO T cells were mixed 1:1 prior to adoptive transfer, there were more than 90% of WT cells (Ly5.1 + ) among total donor CD4 T cells in recipient spleen 2 weeks post-BMT, indicating that the WT CD4 T cells ousted their KO counterparts under the competitive environment (Fig. 5A ). In contrast, the deficiency of miR-17-92 had much less effect on 1 1 the expansion of CD8 T cells (Fig. 5A) . Consistently, the percentage of BrdU-labeled cells was significantly reduced in KO CD4 T cells, but comparable in KO CD8 T cells compared to WT counterparts in recipient spleens (Fig. 5B) . We also calculated the ratio of KO/WT T cells in recipients in order to evaluate the impact of miR-17-92 on donor T-cell expansion in the spleen and migration into GVHD target organs including the liver, gut, and lung. The ratio of KO/WT CD4 T cells was dramatically reduced in allogenic recipients, but the ratio in each of those target organs was comparable to that in the spleen (Fig. 5C ), suggesting that miR-17-92 effects CD4 T-cell expansion.
On the other hand, the ratio of KO/WT CD8 T cells was significantly reduced in gut and lung as compared to the spleen ( affects T-cell responses intrinsically and regulates CD4 vs. CD8 in a different manner.
miR-17-92 is dispensable to the GVL activity and CD8 T-cell cytolytic function
We next asked the critical question as to whether T cells deficient for miR-17-92 maintain their GVL activity. To test this, we infused host-type B cell lymphoma (A20) together with BM or BM plus T cells into lethally irradiate allogeneic recipients. As expected, all the recipients without T cell infusion died from lymphoma relapse within 30 days after BMT (Fig. S8A) . When receiving 0.5×10 6 /mouse T cells, all the recipients of WT T cells died from GVHD (except one from tumor relapse) based on their survival (Fig. S8A ), body weight loss (Fig. S8B) , and tumor signal (Fig. S8C) . In contrast, the For personal use only. on November 1, 2017. by guest www.bloodjournal.org From recipients of KO T cells at the same dose survived without GVHD and were largely free from tumor relapse. Furthermore, when receiving 1.0×10 6 /mouse of T cells, all the recipients of WT T cells died from GVHD without tumor relapse, whereas all the recipients of KO T cells have long-term survive without severe GVHD or tumor relapse ( Fig. S8D-E) . Taken together, these data suggest that the KO T cells had preserved GVL activity in the MHC-mismatched BMT model.
To exclude the possibility that the preserved GVL activity is model specific, we utilized haploidentical B6→BDF1 BMT model with more aggressive p815 mastocytoma. All the recipients without T cell infusion died from leukemia relapse within 20 days after BMT (Fig. 6A) , whereas the recipients of WT T cells died from GVHD reflected by 100% lethality (Fig. 6A ), severe weight loss (Fig. 6B) , and no tumor signal (Fig. 6C) . In contrast, the vast majority of the recipients transplanted with KO T cells survived without GVHD or tumor relapse. To confirm the GVL activity, we tested higher doses of p815 that caused accelerated tumor relapse in the recipients without T-cell infusion ( Fig. 6D-E) .
Although the mortality due to tumor relapse was comparable regardless of T-cell type (Fig. 6E) , the recipients of KO T cells had improved survival (Fig. 6D ) compared to those of WT T cells. These results indicate that miR-17-92 is essential for donor T cells to induce GVHD but not to mediate the GVL effect. To understand the potential mechanisms by which T cells deficient for miR-17-92 had impaired ability to induce GVHD while preserving GVL activity, we examined the expression of cytolytic molecules on donor CD8 T cells. As compared with WT T cells, the KO CD8 T cells expressed lower levels of granzyme B or CD107a, similar levels of IFNγ, and higher levels of TNFα proportionally (Fig. 6F) . Furthermore, the absolute numbers of KO CD8 T cells expressing those effector molecules in recipient spleens were comparable to WT cells (Fig. 6G) . We reason that residual granzyme B, IFNγ, and/or TNFα in KO CD8 T cells are responsible for their preserved GVL activity.
3
Targeting miR-17 or -19b using specific LNA antagomirs inhibits T-cell alloresponse and alleviates GVHD Strong evidence demonstrates that LNA antagomirs can specifically and effectively block target miRs.
9,26 Furthermore, the LNA antagomirs specific for the members in the miR-17-92 cluster have been tested and shown to be effective in blocking the function of this cluster and inhibiting tumor progression. 27, 28 By reconstituting miR-17-92 whole cluster deficient T cells with individual miRs, the study by Jiang et al reveals that miR-17 and miR-19b among miR-17-92 cluster are the key players in controlling Th1 responses. 14 We thus designed LNA antagomirs that can specifically target miR-17 seed family (miR-17 and miR-20a) or miR-19 seed family (miR-19a and miR-19b-1) (sequences highlighted in Fig. S1 ). We then tested the effect of these LNA antagomirs on T-cell expansion and activation in allogeneic recipients. In comparison with scrambled control, anti-miR-17 significantly reduced donor CD4 and CD8 T-cell expansion (Fig. 7A-B ) and IFNγ production (Fig. 7C-D) . The effect of anti-miR-19 was more profound than that of anti-miR-17 (Fig. 7A-D) . Furthermore, systemic treatment with anti-miR-17 or anti-miR-19 significantly reduced recipient mortality compared with the scrambled control group (Fig. 7E , p < .05, p < .01, respectively). Since blocking miR-19 was more effective to alleviate GVHD, we further evaluated the effect of anti-miR-19 on the GVL activity ( showed prolonged survival ( Fig. 7F ) and comparable mortality due to tumor relapse as those with scrambled antagomir (Fig. 7G and Fig. S9 ). These data suggest that pharmacologically blocking the key member of the miR-17-92 cluster efficiently constrains T-cell alloresponses and thus attenuates GVHD while preserving GVL activity.
1 4
Discussion
Primarily using a genetic approach, our data demonstrates that the miR-17-92 cluster intrinsically controls multiple aspects of the T-cell response to alloantigens and regulates CD4 and CD8 T cells in a different manner. The miR-17-92 strongly enhances activation, survival, and proliferation of CD4 T cells. In addition, this cluster is critical for Th1 differentiation, but is suppressive for Th2 and iTreg differentiation. In contrast to CD4 T cells, miR-17-92 has no impact on cell survival, decreased effect on proliferation and cytolytic function, but may promote migration of CD8 T cells. As a result, the expression of miR-17-92 on donor T cells is essential for the induction of GVHD but not for the mediation of the GVL effect after allo-BMT. Furthermore, pharmacological blockade of miR-17 or miR-19b is effective in controlling T-cell alloresponses and attenuating GVHD severity.
In the current study, we have provided compelling evidence that miR-17-92 is required for T cells to induce GVHD. T cells deficient for miR-17-92 were essentially unable to mediate GVHD in all 3 allogeneic BMT models tested: MHC-mismatched ( Fig. 2A-B) , MHC-matched but MiHA-mismatched (Fig. 2E-F) , and haploidentical (Fig. 6 ) models. Mechanistically, we first observed that CD4 T cells deficient for miR-17-92 dramatically decreased expansion both on day 4 (Fig. 1A-B ) and 14 (Fig. 3A) after allo-BMT. Decreased expansion likely resulted from reduced proliferation (Fig. 1C-D ) and increased AICD (Fig. 1G-H ) in alloantigen-driven response in vivo. Unexpectedly, the cell death rate was significantly decreased on KO CD4 T cells that were undergoing slow or no cell division (CFSE high ) (Fig. 1G-H) . Consistently, the KO CD4 T cells had lower rates of cell death and expressed higher levels of Bcl-2 compared with WT T cells once being transferred into irradiated syngeneic recipients (data not shown). Thus, miR-17-92 protects CD4 T cells from extrinsic apoptosis under alloantigen-driven proliferation whereas it promotes intrinsic apoptosis under homeostatic proliferation, which is likely because miR-17-92 negatively regulates PTEN during T-cell activation with antigens 1 5
and may also negatively regulate Bcl-2 during T-cell maintenance. 12 As a consequence, it is plausible that inhibition of miR-17-92 would specifically or preferentially suppress an alloantigen-driven response while preserving T-cell homeostasis, which would benefit patients with GVHD without causing broad immune suppression.
In accordance with the published report that miR-17-92 promotes IFNγ production in vitro and Th1 differentiation in delayed-type hypersensitivity in vivo, 14 we found that miR-17-92 was essential for optimal differentiation to Th1 cells following allo-BMT (Fig. 4) . Given that GVHD is primarily driven by Th1 cells, we surmised that compromised Th1 differentiation largely accounts for the impaired ability of miR-17-92 KO T cells to induce GVHD. In parallel to compromised Th1 differentiation, T cells deficient for miR-17-92 substantially enhanced differentiation into less pathogenic Th2 cells and suppressive iTregs (Fig. 4) . A recent report from Bluestone's group showed that natural Tregs deficient for miR-17-92 do not retain suppressive function due to loss of IL-10 production. 29 However, we found that the suppressive function of iTregs generated from KO and WT CD4 T cells in vitro had comparable suppressive function (Fig. S7) . Thus, we reason that iTregs generated from KO T cells likely contributed to the alleviated GVHD.
Donor T-cell infiltration into target organs is a prerequisite for GVHD development; chemokine receptors and integrins play important roles in T-cell migration to GVHD target organs. 30 We found that there were significantly fewer KO T cells in recipient livers than their WT counterparts (Fig. 3) .
Both the expansion and migration ability of T cells contribute to the number of donor T cells present in a target organ. In a competitive environment, the deficiency of this cluster dramatically reduced the expansion on CD4 but less on CD8 T cells, and it may further reduce migration of CD8 T cells (Fig.   5A-C) . Furthermore, miR-17-92 deficient T cells expressed significantly lower levels of CXCR3 and Of clinical importance, we demonstrated that miR-17-92 was dispensable for T cell-mediated GVL effect in 2 preclinical BMT models (Fig. S8 and Fig. 6 ). We attribute the preserved GVL effect to largely intact CTL activation and function in the absence of miR-17-92. There are several lines of evidence to support this: 1) miR-17-92 had no effect on the survival of CD8 T cells after BMT (Fig. 1 G-H); 2) although CD8 T cells deficient for miR-17-92 showed decreased proliferation in the early phase of BMT (Fig. 1C-D) , their expansion was not significantly compromised in the later phase of BMT (Fig. 3A) . Our observation is consistent with published findings that over-expression of miR-17-92 in lymphocytes induces a major expansion in the CD4 but to a lesser extent in the CD8 T cells; 11 3) miR-17-92 deficiency may impair CD8 T-cell migration rather than substantially reducing proliferation ( Fig. 3 and Fig. 5) ; 4) miR-17-92 had little or no effect on cytolytic activity, reflected by levels of granzyme B and CD107a, and cytokine production, reflected by intracellular expression of IFNγ (Fig. 6F-G) . It is worthy to point out that both CD4 (data not shown) and CD8 T cells had increased TNFα production in the absence of miR-17-92 (Fig. 6F) , which is consistent with a previous report that TNFα is a target of miR-19a. 33 Given TNFα is a GVL mediator, 34,35 elevated TNFα production by donor T cells may also contribute to the preserved GVL effect.
Using a translational approach, we demonstrate that blocking miR-17 or miR-19b by using specific
LNA antagomirs significantly reduced T-cell proliferation and activation under the stimulation of
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From alloantigens and further attenuated the severity of GVHD while preserving GVL activity (Fig. 7 and   Fig. S9) . Although not to the extent of miR-17-92 deficiency, the effect of antagomir-treatment was quite remarkable, given only a single member of this cluster was inhibited. Our study provides the rationale to establish the significance of miR-17-92 in GVHD and to target this cluster for GVHD prophylaxis in the clinic. As a novel therapeutic strategy, several miR modulators have entered into clinical trials. 36 Moreover, antagomirs can be relatively easily delivered into primary lymphocytes ex vivo prior to BMT, 37,38 which may lead to a higher efficiency and specificity in knocking-down miRs in T and B cells prior to transfer and thus result in effective prevention of GVHD with low toxicity.
miR-17-92, also known as polycistronic oncomir-1, is overexpressed in many types of malignancies, 13 and a strategy to silence this cluster to suppress solid tumor growth has been established in preclinical models. 27,28 Therefore, we anticipate that within the foreseeable future the translational feasibility of silencing miR-17-92 will be achieved, which will significantly benefit cancer patients, especially those with hematologic malignancies following allo-HCT. 
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